SCHEMBL2279271

SCHEMBL2279271

CON(C(C)=O)c1cccc(/C=C/C(=O)c2c(O)cc(C)n(C)c2=O)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 2/20 0.41
MAOB P27338 2/20 0.41
CYP19A1 P11511 1/20 0.41
CYP2C9 P11712 1/20 0.41
MAOA P21397 1/20 0.41
CYP2C19 P33261 1/20 0.41
ABCB1 P08183 3/20 0.39
MAPT P10636 5/20 0.39
KMT2A Q03164 3/20 0.39
NPSR1 Q6W5P4 2/20 0.39
MEN1 O00255 2/20 0.39
KCNA3 P22001 1/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
USP2 O75604 1/20 0.38
POLB P06746 1/20 0.38
RECQL P46063 1/20 0.38
TP53 P04637 1/20 0.38
CYP3A4 P08684 1/20 0.38
ATM Q13315 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2278728 0.89 ABCG2 (0.43) ABCG2ABCB1MAPTKMT2ANPSR1
SCHEMBL2275775 0.83 LMNA (0.45) ABCG2MAOBCYP19A1CYP2C9MAOA
SCHEMBL2281391 0.83 MAOA (0.51) ABCG2MAOBCYP19A1CYP2C9MAOA
SCHEMBL2281390 0.83 MAOA (0.51) ABCG2MAOBCYP19A1CYP2C9MAOA
SCHEMBL2278723 0.81 TTR (0.47) ABCG2MAOBCYP19A1CYP2C9MAOA
SCHEMBL2278721 0.81 TTR (0.47) ABCG2MAOBCYP19A1CYP2C9MAOA
SCHEMBL3493929 0.81 LMNA (0.34) MAOBCYP19A1CYP2C9MAOACYP2C19
SCHEMBL3530409 0.81 MAPT (0.60) ABCG2MAOBCYP19A1CYP2C9MAOA
SCHEMBL15233123 0.81 MAOA (0.49) ABCG2MAOBCYP19A1CYP2C9MAOA
SCHEMBL5630005 0.79 P4HB (0.58) ABCG2MAOBCYP19A1CYP2C9MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 ABCG2 4878/4885MAOB 3699/4885CYP19A1 1821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.